<PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">39331315</PMID><DateRevised><Year>2024</Year><Month>09</Month><Day>27</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1556-2891</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2024</Year><Month>Sep</Month><Day>27</Day></PubDate></JournalIssue><Title>Forensic science, medicine, and pathology</Title><ISOAbbreviation>Forensic Sci Med Pathol</ISOAbbreviation></Journal><ArticleTitle>Hereditary thrombophilia as a possible risk factor for severe disease in COVID-19: a case series.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.1007/s12024-024-00879-4</ELocationID><Abstract><AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">The risk factors that modulate one's susceptibility for severe COVID-19 have been well documented. Despite this, hypercoagulability remains an often overlooked risk factor for severe disease for COVID-19. Because COVID-19 infection is a risk factor for hypercoagulability, a reasonable presumption/hypothesis is that patients with hereditary thrombophilia would be at a higher risk of thrombotic complications associated with COVID-19 infection.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">This case report details two cases where previously unknown hereditary thrombophilias likely contributed to the mortality of COVID-19 patients.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The first COVID-19 patient's cause of death was pulmonary thromboemboli from deep vein thrombosis due to heterozygous MTHFR C667T and heterozygous PAI-1 4G/5G mutations. The second COVID-19 patient's cause of death was an acute myocardial infarct due to a coronary artery thrombosis in the setting of heterozygous MTHFR A1298C and homozygous PAI-1 4G/5G mutations. In each case, COVID-19 infection was also considered contributory to death.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">The occurrence of these fatal thrombotic events in COVID-19 patients with hereditary thrombophilias raises questions as to whether this combination of thrombotic risk factors for hypercoagulability may have placed patients at a significant enough risk to experience these fatal thrombotic complications. Thus, while not sufficient alone to prove that SARS-CoV-2 patients with hereditary thrombophilias are at increased risk for thrombotic complications, these two cases indicate that further investigation is warranted into elucidating the relationship between thrombotic risk factors as it may identify an additional high-risk medical condition for COVID-19 and have important diagnostic and therapeutic ramifications.</AbstractText><CopyrightInformation>© 2024. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Tse</LastName><ForeName>Jonathan</ForeName><Initials>J</Initials><Identifier Source="ORCID">0009-0006-9384-4131</Identifier><AffiliationInfo><Affiliation>Western Michigan University Homer Stryker MD School of Medicine, 300 Portage St. Kalamazoo, Kalamazoo, MI, 49007, USA. Jonathan.tse@wmed.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gongolli</LastName><ForeName>Julita</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Western Michigan University Homer Stryker MD School of Medicine, 300 Portage St. Kalamazoo, Kalamazoo, MI, 49007, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Prahlow</LastName><ForeName>Joseph A</ForeName><Initials>JA</Initials><AffiliationInfo><Affiliation>Department of Pathology, St. Louis University School of Medicine, City of St. Louis, MO, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>27</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Forensic Sci Med Pathol</MedlineTA><NlmUniqueID>101236111</NlmUniqueID><ISSNLinking>1547-769X</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Forensic pathology</Keyword><Keyword MajorTopicYN="N">Hereditary thrombophilia</Keyword><Keyword MajorTopicYN="N">MTHFR</Keyword><Keyword MajorTopicYN="N">PAI-1</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>8</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>9</Month><Day>27</Day><Hour>12</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>9</Month><Day>27</Day><Hour>12</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>9</Month><Day>27</Day><Hour>11</Hour><Minute>21</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39331315</ArticleId><ArticleId IdType="doi">10.1007/s12024-024-00879-4</ArticleId><ArticleId IdType="pii">10.1007/s12024-024-00879-4</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Rashedi J, Mahdavi Poor B, Asgharzadeh V, et al. Risk factors for COVID-19. Infez Med. 2020;28(4):469–74.</Citation><ArticleIdList><ArticleId IdType="pubmed">33257620</ArticleId></ArticleIdList></Reference><Reference><Citation>People with certain medical conditions. In: COVID-19. Centers for Disease Control and Prevention. Published 2020. https://www.cdc.gov/coronavirus/2019-ncov/need-extra-precautions/people-with-medical-conditions.html . Accessed 5 Dec 2023.</Citation></Reference><Reference><Citation>‌Kichloo A, Dettloff K, Aljadah M, et al. COVID-19 and hypercoagulability: a review. Clin Appl Thromb Hemost. 2020. https://doi.org/10.1177/1076029620962853 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1076029620962853</ArticleId><ArticleId IdType="pubmed">33074732</ArticleId><ArticleId IdType="pmc">7592310</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheng NM, Chan YC, Cheng SW. COVID-19 related thrombosis: a mini-review. Phlebology. 2022;37(5):326–37. https://doi.org/10.1177/02683555211052170 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/02683555211052170</ArticleId><ArticleId IdType="pubmed">35403487</ArticleId><ArticleId IdType="pmc">9006089</ArticleId></ArticleIdList></Reference><Reference><Citation>Zuin M, Barco S, Giannakoulas G, et al. Risk of venous thromboembolic events after COVID-19 infection: a systematic review and meta-analysis. J Thromb Thrombolysis. 2023;55(3):490–8. https://doi.org/10.1007/s11239-022-02766-7 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11239-022-02766-7</ArticleId><ArticleId IdType="pubmed">36652137</ArticleId><ArticleId IdType="pmc">9845812</ArticleId></ArticleIdList></Reference><Reference><Citation>Massoud GP, Hazimeh DH, Amin G, et al. Risk of thromboembolic events in non-hospitalized COVID-19 patients: a systematic review. Eur J Pharmacol. 2023;941:175501. https://doi.org/10.1016/j.ejphar.2023.175501 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejphar.2023.175501</ArticleId><ArticleId IdType="pubmed">36641102</ArticleId><ArticleId IdType="pmc">9833853</ArticleId></ArticleIdList></Reference><Reference><Citation>Wheeler HB, Anderson FA Jr, Cardullo PA, Patwardhan NA, Jian-Ming L, Cutler BS. Suspected deep vein thrombosis. Management by impedance plethysmography. Arch Surg. 1982;117(9):1206–9. https://doi.org/10.1001/archsurg.1982.01380330064015 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archsurg.1982.01380330064015</ArticleId><ArticleId IdType="pubmed">6810844</ArticleId></ArticleIdList></Reference><Reference><Citation>Anderson FA Jr, Spencer FA. Risk factors for venous thromboembolism. Circulation. 2003;107(23 Suppl 1):I9–16. https://doi.org/10.1161/01.CIR.0000078469.07362.E6 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/01.CIR.0000078469.07362.E6</ArticleId><ArticleId IdType="pubmed">12814980</ArticleId></ArticleIdList></Reference><Reference><Citation>Giannis D, Ziogas IA, Gianni P. Coagulation disorders in coronavirus infected patients: COVID-19, SARS-CoV-1, MERS-CoV and lessons from the past. J Clin Virol. 2020. https://doi.org/10.1016/j.jcv.2020.104362 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jcv.2020.104362</ArticleId><ArticleId IdType="pubmed">32305883</ArticleId><ArticleId IdType="pmc">7195278</ArticleId></ArticleIdList></Reference><Reference><Citation>Han H, Yang L, Liu R, et al. Prominent changes in blood coagulation of patients with SARS-CoV-2 infection. Clin Chem Lab Med. 2020. https://doi.org/10.1515/cclm-2020-0188 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1515/cclm-2020-0188</ArticleId><ArticleId IdType="pubmed">33001847</ArticleId></ArticleIdList></Reference><Reference><Citation>Abou-Ismail MY, Diamond A, Kapoor S, Arafah Y, Nayak L. The hypercoagulable state in COVID-19: incidence, pathophysiology, and management [published correction appears in Thromb Res. 2020]. Thromb Res. 2020. https://doi.org/10.1016/j.thromres.2020.06.029 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.thromres.2020.06.029</ArticleId><ArticleId IdType="pubmed">33250201</ArticleId><ArticleId IdType="pmc">7691845</ArticleId></ArticleIdList></Reference><Reference><Citation>Ali EW, Ibrahim IK. Multi-factorial mechanism behind COVID-19 related thrombosis. Med Arch. 2022;76(1):62–5. https://doi.org/10.5455/medarh.2022.76.62-65 .</Citation><ArticleIdList><ArticleId IdType="doi">10.5455/medarh.2022.76.62-65</ArticleId><ArticleId IdType="pubmed">35422572</ArticleId><ArticleId IdType="pmc">8976895</ArticleId></ArticleIdList></Reference><Reference><Citation>Hanff TC, Mohareb AM, Giri J, Cohen JB, Chirinos JA. Thrombosis in COVID-19. Am J Hematol. 2020;95(12):1578–89. https://doi.org/10.1002/ajh.25982 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ajh.25982</ArticleId><ArticleId IdType="pubmed">32857878</ArticleId><ArticleId IdType="pmc">7674272</ArticleId></ArticleIdList></Reference><Reference><Citation>Sarkar M, Madabhavi IV, Quy PN, Govindagoudar MB. COVID-19 and coagulopathy. Clin Respir J. 2021;15(12):1259–74. https://doi.org/10.1111/crj.13438 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/crj.13438</ArticleId><ArticleId IdType="pubmed">34399021</ArticleId></ArticleIdList></Reference><Reference><Citation>Baglin T. Inherited and acquired risk factors for venous thromboembolism. Semin Respir Crit Care Med. 2012. https://doi.org/10.1055/s-0032-1311791 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1055/s-0032-1311791</ArticleId><ArticleId IdType="pubmed">22648484</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Q, Jin Y, Li X, et al. Plasminogen activator inhibitor-1 (PAI-1) 4G/5G promoter polymorphisms and risk of venous thromboembolism - a meta-analysis and systematic review. Vasa. 2020. https://doi.org/10.1024/0301-1526/a000839 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1024/0301-1526/a000839</ArticleId><ArticleId IdType="pubmed">32933402</ArticleId></ArticleIdList></Reference><Reference><Citation>Nikolopoulos GK, Bagos PG, Tsangaris I, et al. The association between plasminogen activator inhibitor type 1 (PAI-1) levels, PAI-1 4G/5G polymorphism, and myocardial infarction: a mendelian randomization meta-analysis. Clin Chem Lab Med. 2014. https://doi.org/10.1515/cclm-2013-1124 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1515/cclm-2013-1124</ArticleId><ArticleId IdType="pubmed">24695040</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Y, Cheng J, Guo X, et al. The roles of PAI-1 gene polymorphisms in atherosclerotic diseases: a systematic review and meta-analysis involving 149,908 subjects. Gene. 2018. https://doi.org/10.1016/j.gene.2018.06.040 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.gene.2018.06.040</ArticleId><ArticleId IdType="pubmed">30599236</ArticleId><ArticleId IdType="pmc">6320273</ArticleId></ArticleIdList></Reference><Reference><Citation>Raghubeer S, Matsha TE. Methylenetetrahydrofolate (MTHFR), the one-Carbon cycle, and Cardiovascular risks. Nutrients. 2021. https://doi.org/10.3390/nu13124562 .</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/nu13124562</ArticleId><ArticleId IdType="pubmed">34960114</ArticleId><ArticleId IdType="pmc">8703276</ArticleId></ArticleIdList></Reference><Reference><Citation>Dean L. Methylenetetrahydrofolate Reductase Deficiency. In: Pratt VM, Scott SA, Pirmohamed M, Esquivel B, Kattman BL, Malheiro AJ, eds. Medical Genetics Summaries. Bethesda (MD): National Center for Biotechnology Information (US); March 8, 2012.</Citation></Reference><Reference><Citation>Nappo F, De Rosa N, Marfella R, et al. Impairment of endothelial functions by acute hyperhomocysteinemia and reversal by antioxidant vitamins. JAMA. 1999. https://doi.org/10.1001/jama.281.22.2113 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.281.22.2113</ArticleId><ArticleId IdType="pubmed">10367822</ArticleId></ArticleIdList></Reference><Reference><Citation>Lijfering WM, Veeger NJ, Brouwer JL, van der Meer J. The risk of venous and arterial thrombosis in hyperhomocysteinemic subjects may be a result of elevated factor VIII levels. Haematologica. 2007. https://doi.org/10.3324/haematol.11611 .</Citation><ArticleIdList><ArticleId IdType="doi">10.3324/haematol.11611</ArticleId><ArticleId IdType="pubmed">18055997</ArticleId></ArticleIdList></Reference><Reference><Citation>Martí-Carvajal AJ, Solà I, Lathyris D, Dayer M. Homocysteine-lowering interventions for preventing cardiovascular events. Cochrane Database Syst Rev. 2017. https://doi.org/10.1002/14651858.CD006612.pub5 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/14651858.CD006612.pub5</ArticleId><ArticleId IdType="pubmed">28816346</ArticleId><ArticleId IdType="pmc">6483699</ArticleId></ArticleIdList></Reference><Reference><Citation>Ray JG. Meta-analysis of hyperhomocysteinemia as a risk factor for venous thromboembolic disease. Arch Intern Med. 1998. https://doi.org/10.1001/archinte.158.19.2101 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archinte.158.19.2101</ArticleId><ArticleId IdType="pubmed">9801176</ArticleId></ArticleIdList></Reference><Reference><Citation>Ospina-Romero M, Cannegieter SC, den Heijer M, Doggen CJM, Rosendaal FR, Lijfering WM. Hyperhomocysteinemia and risk of first venous thrombosis: the influence of (unmeasured) confounding factors. Am J Epidemiol. 2018. https://doi.org/10.1093/aje/kwy004 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/aje/kwy004</ArticleId><ArticleId IdType="pubmed">29370361</ArticleId></ArticleIdList></Reference><Reference><Citation>Alizadeh S, Djafarian K, Moradi S, Shab-Bidar S. C667T and A1298C polymorphisms of methylenetetrahydrofolate reductase gene and susceptibility to myocardial infarction: a systematic review and meta-analysis. Int J Cardiol. 2016. https://doi.org/10.1016/j.ijcard.2016.04.181 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijcard.2016.04.181</ArticleId><ArticleId IdType="pubmed">27179899</ArticleId></ArticleIdList></Reference><Reference><Citation>Gao M, Feng N, Zhang M, Ti X, Zuo X. Meta-analysis of the relationship between methylenetetrahydrofolate reductase C677T and A1298C polymorphism and venous thromboembolism in the caucasian and Asian. Biosci Rep. 2020. https://doi.org/10.1042/BSR20200860 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1042/BSR20200860</ArticleId><ArticleId IdType="pubmed">33325526</ArticleId><ArticleId IdType="pmc">7745063</ArticleId></ArticleIdList></Reference><Reference><Citation>Simsek E, Yesilyurt A, Pinarli F, Eyerci N, Ulus AT. Combined genetic mutations have remarkable effect on deep venous thrombosis and/or pulmonary embolism occurrence. Gene. 2014. https://doi.org/10.1016/j.gene.2014.02.046 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.gene.2014.02.046</ArticleId><ArticleId IdType="pubmed">24334115</ArticleId></ArticleIdList></Reference><Reference><Citation>Levin BL, Varga E. MTHFR: addressing genetic counseling dilemmas using evidence-based literature. J Genet Couns. 2016. https://doi.org/10.1007/s10897-016-9956-7 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10897-016-9956-7</ArticleId><ArticleId IdType="pubmed">27130656</ArticleId></ArticleIdList></Reference><Reference><Citation>Middeldorp S, Nieuwlaat R, Baumann Kreuziger L, et al. American Society of Hematology 2023 Guidelines for Management of venous thromboembolism: Thrombophilia Testing [published online ahead of print, 2023 May 17]. Blood Adv. 2023. https://doi.org/10.1182/bloodadvances.2023010177 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/bloodadvances.2023010177</ArticleId><ArticleId IdType="pubmed">37195076</ArticleId><ArticleId IdType="pmc">10709681</ArticleId></ArticleIdList></Reference><Reference><Citation>Badulescu OV, Sirbu PD, Filip N, et al. Hereditary Thrombophilia in the era of COVID-19. Healthc (Basel). 2022;10(6):993. https://doi.org/10.3390/healthcare10060993 . Published 2022 May 27.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/healthcare10060993</ArticleId></ArticleIdList></Reference><Reference><Citation>Kovac M, Mitic G, Milenkovic M, et al. Thrombosis risk assessment in patients with congenital thrombophilia during COVID – 19 infection. Thromb Res. 2022;218:151–6. https://doi.org/10.1016/j.thromres.2022.08.020 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.thromres.2022.08.020</ArticleId><ArticleId IdType="pubmed">36054979</ArticleId><ArticleId IdType="pmc">9392558</ArticleId></ArticleIdList></Reference><Reference><Citation>Elbadry MI, Tawfeek A, Abdellatif MG et al. Unusual pattern of thrombotic events in young adult non-critically ill patients with COVID-19 may result from an undiagnosed inherited and acquired form of thrombophilia [published correction appears in Br J Haematol. 2022;198(1):214. https://doi.org/10.1111/bjh.18301 . Br J Haematol. 2022;196(4):902–922. doi: https://doi.org/10.1111/bjh.17986 .</Citation></Reference></ReferenceList></PubmedData></PubmedArticle>